Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention

References

• West of Scotland Coronary Prevention Study Group, Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia. N Engl J Med 1995;333:1301–7
   Google Scholar
• Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344: 1383–9
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E; for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9
   Google Scholar
• Long-term Intervention with Pravastatin Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57
   Google Scholar
• National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333–445
   PubMed Web of Science ®Google Scholar
• Isaacsohn JL, Davidson MH, Hunninghake D, Singer R, McLain R, Black DM. Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE). Rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol 2000;86:250–2
   Google Scholar
• EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE-II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• Forrester JS, Bairey-Merz CN, Sanjay Kaul S. The aggressive low density lipoprotein lowering controversy. JACC 2000;36:1419–25
   Google Scholar
• Mikhailidis DP, Wierzbicki AS. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000;16:139–46
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C; ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety (the ACCESS) Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88: 265–9
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446–52
   PubMed Web of Science ®Google Scholar
• Packard CJ. Relationship between LDL-C changes and CHD event reduction with pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS) (abstr). Circulation 1997;96:(Suppl I) p. 07
   Google Scholar
• Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153–62
   PubMed Web of Science ®Google Scholar
• Atorvastatin versus Revascularization Treatment Investigators, Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70–6
   Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–18
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hyper-cholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577–81
   PubMed Web of Science ®Google Scholar
• Heart Protection Study. http://www.ctsu.ox.ac.uk/~hps/
   Google Scholar
• Kolovou G. The Treatment of Coronary Heart Disease: Statins beyond cholesterol lowering. Curr Med Res Opin 2001;17:34–7
   PubMed Web of Science ®Google Scholar
• Bickel C, Rupprecht HJ, Blankenberg S, Espinola-Klein C, Rippin G, Hafner G, Lotz J, Prellwitz W, Meyer J. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002;82:25–31
   Google Scholar
• Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, Schmetterer L, Dorner GT. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001;85:47–51
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933–5
   Google Scholar
• Cohen JD, Drury JH, Ostdiek J, Finn J, Veerendra Babu BR, Flaker G, Belew K, Donohue T, Labovitz A. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events? Am Heart J 2000;139:734–8
   PubMed Web of Science ®Google Scholar
• Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61–9
   PubMed Web of Science ®Google Scholar
• Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;31:2442–9
   Google Scholar
• Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000;152: 359–66
   Google Scholar
• Tesfamariam B, Frohlich BH, Gregg RE. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999;34: 95–101
   PubMed Web of Science ®Google Scholar
• Pehlivanidis A, Athyros V, Demitriadis D, Papageorgiou A, Bouloukos V, Kontopoulos A. Heart Rate Variability after long-term treatment with atorvastatin in hypercholestero-laemic patients with or without coronary artery disease. Atherosclerosis 2001;157:463–9
   PubMed Web of Science ®Google Scholar
• Cripps TR, Malik M, Farell T, Camm AJ. Prognostic value of reduction of heart rate variability after acute myocardial infarction: clinical evaluation of a new analysis method. Br Heart J 1991;65:14–19
   PubMedGoogle Scholar
• Quintana M, Storck N, Lindblad, Lindvall K, Ericson M. Heart rate variability as a means of assessing prognosis after acute myocardial infarction. Eur Heart J 1997;18:789–97
   PubMed Web of Science ®Google Scholar
• Kontopoulos A, Athyros V, Pehlivanidis A, Demitriadis D, Papageorgiou A, Boudoulas H. Effects of long-term treatment with atorvastatin on aortic elasticity in hypercholesterolemic patients with or without coronary heart disease. Submitted for publication.
   Google Scholar
• Benetos A, Safar M, Rudnichi A, Smulyan H, Richard J, Ducimetière P, Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997;30:1410–15
   PubMed Web of Science ®Google Scholar
• Toikka JO, Niemi P, Ahotupa M, Niinikoski H, Viikari JSA, Rannemaa T, Hartiala JJ, Raitakari OT. Large-artery elastic properties in young men. Relationships to serum lipoproteins and oxidized low-density lipoproteins. Arterioscler Thromb Vasc Biol 1999;19:436–41
   PubMed Web of Science ®Google Scholar
• Zhu Q, McMaster J, Mymin D, Dembinski T, Hatch G, Choy PC, Kroeger EA. Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients. Mol Cell Biochem 2000;207:9–17
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998;138:271–80
   PubMed Web of Science ®Google Scholar
• Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999;15:47–74
   PubMed Web of Science ®Google Scholar
• Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J 1998;19 (Suppl C):C59–65
   PubMedGoogle Scholar
• Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332–6
   Web of Science ®Google Scholar
• Szucs TD, Berger K, Marz W, Schafer JR. Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial. Herz 2000;25:487–94
   Google Scholar
• Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998;137:Suppl:S111–16
   Google Scholar
• Huse DM, Russell MW, Miller JD, Kraemer DF, D’Agostino RB, Ellison RC, Hartz SC. Cost-effectiveness of statins. Am J Cardiol 1998;82:1357–63
   PubMed Web of Science ®Google Scholar
• Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001;8:9–16
   PubMedGoogle Scholar
• Elliott WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm 1999;56:1726–32
   PubMed Web of Science ®Google Scholar